Cardiol Therapeutics Inc. - President & CEO, David Elsley.
President & CEO, David Elsley.
Source: YouTube
  • Cardiol Therapeutics Inc. (CRDL) has started its phase two open-label pilot study investigating CardiolRx in patients with recurrent pericarditis
  • Recurrent pericarditis refers to subsequent inflammation of the membrane that surrounds the heart
  • CardiolRx is the company’s lead oral solution formula developed for use in heart diseases
  • The primary efficacy endpoint is the change in patient-reported pericarditis pain over eight weeks
  • Cardiol Therapeutics Inc. (CRDL) is up 0.99 per cent, trading at $1.02 per share as of 2:33 p.m. EST

Cardiol Therapeutics (CRDL) has started its phase two pilot study of CardiolRx in patients with recurrent pericarditis.

Recurrent pericarditis refers to subsequent inflammation of the membrane that surrounds the heart after an initial incident. Symptoms can include debilitating chest pain, shortness of breath, and fatigue.

Cardiol Therapeutics’ lead product candidate, CardiolRx, is a pharmaceutically manufactured oral solution formula being clinically developed for use in heart diseases.

The company’s phase two pilot study is expected to test 25 patients at clinical centres in the U.S. that specialize in pericarditis care. The primary efficacy endpoint is the change in patient-reported pericarditis pain using an 11-point numeric rating scale over eight weeks.

David Elsley, Cardiol Therapeutics’ President and CEO, commented,

“The data generated from patients who enroll in the study at our collaborating research centres will provide further information in support of the use of CardiolRx™ as a novel therapy for this debilitating and frequently undertreated disorder.”

Secondary endpoints include the pain score after 26 weeks of treatment and changes in circulating levels of C-reactive protein, a commonly used clinical marker for inflammation.

The study was also designed to evaluate improvement in objective measures of disease and, during an extension period, assess the feasibility of weaning parallel background therapy, including corticosteroids, while taking CardiolRx.

Cardiol Therapeutics Inc. (CRDL) is up 0.99 per cent, trading at $1.02 per share as of 2:33 p.m. EST.


More From The Market Online

Optimi Health to advance psychedelic clinical trials

Optimi Health (CSE:OPTI) signs letter of intent with ATMA Journey Centers to advance its psilocybin extract into a psilocybin clinical trial.

@ the Bell: TSX falls in energy sell off

Canada’s main stock index loses ground from sagging commodity prices, but tech shares provide most of the gains on the TSX on Wednesday.
Hudbay Minerals - President and CEO, Peter Kukielski.

Hudbay signs US$300M financing to advance B.C. copper project

Hudbay Minerals (TSX:HBM) plans to raise US$300.2 million in an equity offering to help fund near-term growth at its Copper Mountain unit.